Clinical course of pathologically confirmed corticobasal degeneration and corticobasal syndrome
Abstract The clinical presentation of corticobasal degeneration is diverse, while the background pathology of corticobasal syndrome is also heterogeneous. Therefore, predicting the pathological background of corticobasal syndrome is extremely difficult. Herein, we investigated the clinical findings...
Gespeichert in:
Veröffentlicht in: | Brain communications 2023, Vol.5 (6), p.fcad296 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Abstract
The clinical presentation of corticobasal degeneration is diverse, while the background pathology of corticobasal syndrome is also heterogeneous. Therefore, predicting the pathological background of corticobasal syndrome is extremely difficult. Herein, we investigated the clinical findings and course in patients with pathologically, genetically and biochemically verified corticobasal degeneration and corticobasal syndrome with background pathology to determine findings suggestive of background disorder. Thirty-two patients were identified as having corticobasal degeneration. The median intervals from the initial symptoms to the onset of key milestones were as follows: gait disturbance, 0.0 year; behavioural changes, 1.0 year; falls, 2.0 years; cognitive impairment, 2.0 years; speech impairment, 2.5 years; supranuclear gaze palsy, 3.0 years; urinary incontinence, 3.0 years; and dysphagia, 5.0 years. The median survival time was 7.0 years; 50% of corticobasal degeneration was diagnosed as corticobasal degeneration/corticobasal syndrome at the final presentation. Background pathologies of corticobasal syndrome (n = 48) included corticobasal degeneration (33.3%), progressive supranuclear palsy (29.2%) and Alzheimer’s disease (12.5%). The common course of corticobasal syndrome was initial gait disturbance and early fall. In addition, corticobasal degeneration–corticobasal syndrome manifested behavioural change (2.5 years) and cognitive impairment (3.0 years), as the patient with progressive supranuclear palsy–corticobasal syndrome developed speech impairment (1.0 years) and supranuclear gaze palsy (6.0 years). The Alzheimer’s disease–corticobasal syndrome patients showed cognitive impairment (1.0 years). The frequency of frozen gait at onset was higher in the corticobasal degeneration–corticobasal syndrome group than in the progressive supranuclear palsy–corticobasal syndrome group [P = 0.005, odds ratio (95% confidence interval): 31.67 (1.46–685.34)]. Dysarthria at presentation was higher in progressive supranuclear palsy–corticobasal syndrome than in corticobasal degeneration–corticobasal syndrome [P = 0.047, 6.75 (1.16–39.20)]. Pyramidal sign at presentation and personality change during the entire course were higher in Alzheimer’s disease–corticobasal syndrome than in progressive supranuclear palsy–corticobasal syndrome [P = 0.011, 27.44 (1.25–601.61), and P = 0.013, 40.00 (1.98–807.14), respectively]. In corticobasal syndrome, decision tree analys |
---|---|
ISSN: | 2632-1297 2632-1297 |
DOI: | 10.1093/braincomms/fcad296 |